Intralenticular ozurdex® - One year later

Kathleen A. Regan; Charles R. Blake; Zachary L. Lukowski; Siva S.R. Iyer

doi:10.1159/000485318

Intralenticular ozurdex® - One year later

Kathleen A. Regan, Charles R. Blake, Zachary L. Lukowski, Siva S.R. Iyer

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

Original language	English (US)
Pages (from-to)	590-594
Number of pages	5
Journal	Case Reports in Ophthalmology
Volume	8
Issue number	3
DOIs	https://doi.org/10.1159/000485318
State	Published - Sep 14 2017
Externally published	Yes

Keywords

Diabetic macular edema
Intralenticular dexamethasone implantation (Ozurdex®)
Nuclear sclerotic cataract

ASJC Scopus subject areas

Ophthalmology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000485318

Cite this

@article{02000abeffe9418499bc8e9ede9ddf74,

title = "Intralenticular ozurdex{\textregistered} - One year later",

abstract = "Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex{\textregistered}, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.",

keywords = "Diabetic macular edema, Intralenticular dexamethasone implantation (Ozurdex{\textregistered}), Nuclear sclerotic cataract",

author = "Regan, {Kathleen A.} and Blake, {Charles R.} and Lukowski, {Zachary L.} and Iyer, {Siva S.R.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = sep,

day = "14",

doi = "10.1159/000485318",

language = "English (US)",

volume = "8",

pages = "590--594",

journal = "Case Reports in Ophthalmology",

issn = "1663-2699",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Intralenticular ozurdex® - One year later

AU - Regan, Kathleen A.

AU - Blake, Charles R.

AU - Lukowski, Zachary L.

AU - Iyer, Siva S.R.

PY - 2017/9/14

Y1 - 2017/9/14

N2 - Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

AB - Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

KW - Diabetic macular edema

KW - Intralenticular dexamethasone implantation (Ozurdex®)

KW - Nuclear sclerotic cataract

UR - http://www.scopus.com/inward/record.url?scp=85038638775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038638775&partnerID=8YFLogxK

U2 - 10.1159/000485318

DO - 10.1159/000485318

M3 - Article

AN - SCOPUS:85038638775

SN - 1663-2699

VL - 8

SP - 590

EP - 594

JO - Case Reports in Ophthalmology

JF - Case Reports in Ophthalmology

IS - 3

ER -

Intralenticular ozurdex® - One year later

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this